FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116777199> ?p ?o ?g. }

• W2116777199 endingPage "713" @default.
• W2116777199 startingPage "705" @default.
• W2116777199 abstract "Objective To determine the skeletal effects of alendronate therapy in men with primary hyperparathyroidism (PHPT) in comparison with those in postmenopausal women. Methods There essentially are no published data on the effects of bisphosphonate therapy in men with PHPT. We previously conducted a double-blind, randomized, single-crossover trial of alendronate, 10 mg daily, in PHPT and reported that alendronate significantly increases bone mineral density (BMD) at 12 months relative to baseline values. That study sample included both women (n = 28) and men (n = 9) and both premenopausal (n = 4) and postmenopausal (n = 24) women. Study subjects were randomly assigned to receive either alendronate or placebo during the first year, and all subjects received alendronate during the second year. Among the men, 3 received alendronate and 6 received placebo during the first year. The current analysis focuses on the skeletal effects of alendronate therapy in the 9 men during their first year of treatment versus the 6 men during their first year while receiving placebo as well as the 24 postmenopausal women during their first year of alendronate therapy. Paired t tests comparing baseline and 12-month data were performed for the 9 treated men and the 6 control subjects; unpaired t tests were used to compare the 9 treated men and the 24 treated women. Results Alendronate therapy for 1 year (n = 9) resulted in a 4.8% increase in BMD at the lumbar spine (P = .1) in comparison with the men who received 1 year of placebo (n = 6). Relative to baseline, men receiving alendronate showed a significant 4.4% gain in BMD at the lumbar spine (P = .009) and a 2.95% gain in total hip BMD (P = .027). A 47% decline in serum levels of bone-specific alkaline phosphatase activity was also noted with alendronate therapy (P = .003). Changes in BMD in the male population were similar to previously reported effects of alendronate therapy in postmenopausal women with PHPT. Conclusion Alendronate therapy in men with PHPT is associated with improvements in BMD and reductions in bone turnover. These data, similar to the findings in postmenopausal women with PHPT, suggest that aminobisphosphonates may be of value in providing skeletal protection for men with PHPT. Further study is needed to confirm skeletal protection and fracture efficacy in this population. (Endocr Pract. 2009;15:705-713)" @default.
• W2116777199 created "2016-06-24" @default.
• W2116777199 creator A5009397846 @default.
• W2116777199 creator A5013126573 @default.
• W2116777199 creator A5045240469 @default.
• W2116777199 creator A5063080270 @default.
• W2116777199 creator A5072824419 @default.
• W2116777199 creator A5074125014 @default.
• W2116777199 date "2009-11-01" @default.
• W2116777199 modified "2023-10-01" @default.
• W2116777199 title "Alendronate Therapy in Men With Primary Hyperparathyroidism" @default.
• W2116777199 cites W1970517193 @default.
• W2116777199 cites W1994415434 @default.
• W2116777199 cites W2016622147 @default.
• W2116777199 cites W2022792809 @default.
• W2116777199 cites W2024909412 @default.
• W2116777199 cites W2064584518 @default.
• W2116777199 cites W2111445333 @default.
• W2116777199 cites W2113108574 @default.
• W2116777199 cites W2124835329 @default.
• W2116777199 cites W2141096951 @default.
• W2116777199 cites W2144102059 @default.
• W2116777199 cites W2313541363 @default.
• W2116777199 cites W4253205304 @default.
• W2116777199 doi "https://doi.org/10.4158/ep08178.orr" @default.
• W2116777199 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4357232" @default.
• W2116777199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19625240" @default.
• W2116777199 hasPublicationYear "2009" @default.
• W2116777199 type Work @default.
• W2116777199 sameAs 2116777199 @default.
• W2116777199 citedByCount "51" @default.
• W2116777199 countsByYear W21167771992012 @default.
• W2116777199 countsByYear W21167771992013 @default.
• W2116777199 countsByYear W21167771992014 @default.
• W2116777199 countsByYear W21167771992015 @default.
• W2116777199 countsByYear W21167771992016 @default.
• W2116777199 countsByYear W21167771992017 @default.
• W2116777199 countsByYear W21167771992018 @default.
• W2116777199 countsByYear W21167771992019 @default.
• W2116777199 countsByYear W21167771992020 @default.
• W2116777199 countsByYear W21167771992021 @default.
• W2116777199 countsByYear W21167771992022 @default.
• W2116777199 countsByYear W21167771992023 @default.
• W2116777199 crossrefType "journal-article" @default.
• W2116777199 hasAuthorship W2116777199A5009397846 @default.
• W2116777199 hasAuthorship W2116777199A5013126573 @default.
• W2116777199 hasAuthorship W2116777199A5045240469 @default.
• W2116777199 hasAuthorship W2116777199A5063080270 @default.
• W2116777199 hasAuthorship W2116777199A5072824419 @default.
• W2116777199 hasAuthorship W2116777199A5074125014 @default.
• W2116777199 hasBestOaLocation W21167771992 @default.
• W2116777199 hasConcept C126322002 @default.
• W2116777199 hasConcept C126894567 @default.
• W2116777199 hasConcept C141071460 @default.
• W2116777199 hasConcept C142724271 @default.
• W2116777199 hasConcept C168563851 @default.
• W2116777199 hasConcept C204787440 @default.
• W2116777199 hasConcept C27081682 @default.
• W2116777199 hasConcept C2776541429 @default.
• W2116777199 hasConcept C2776886416 @default.
• W2116777199 hasConcept C2777251235 @default.
• W2116777199 hasConcept C2779053571 @default.
• W2116777199 hasConcept C2779809032 @default.
• W2116777199 hasConcept C3018603563 @default.
• W2116777199 hasConcept C71924100 @default.
• W2116777199 hasConceptScore W2116777199C126322002 @default.
• W2116777199 hasConceptScore W2116777199C126894567 @default.
• W2116777199 hasConceptScore W2116777199C141071460 @default.
• W2116777199 hasConceptScore W2116777199C142724271 @default.
• W2116777199 hasConceptScore W2116777199C168563851 @default.
• W2116777199 hasConceptScore W2116777199C204787440 @default.
• W2116777199 hasConceptScore W2116777199C27081682 @default.
• W2116777199 hasConceptScore W2116777199C2776541429 @default.
• W2116777199 hasConceptScore W2116777199C2776886416 @default.
• W2116777199 hasConceptScore W2116777199C2777251235 @default.
• W2116777199 hasConceptScore W2116777199C2779053571 @default.
• W2116777199 hasConceptScore W2116777199C2779809032 @default.
• W2116777199 hasConceptScore W2116777199C3018603563 @default.
• W2116777199 hasConceptScore W2116777199C71924100 @default.
• W2116777199 hasIssue "7" @default.
• W2116777199 hasLocation W21167771991 @default.
• W2116777199 hasLocation W21167771992 @default.
• W2116777199 hasLocation W21167771993 @default.
• W2116777199 hasOpenAccess W2116777199 @default.
• W2116777199 hasPrimaryLocation W21167771991 @default.
• W2116777199 hasRelatedWork W2071508609 @default.
• W2116777199 hasRelatedWork W2091961110 @default.
• W2116777199 hasRelatedWork W2183240513 @default.
• W2116777199 hasRelatedWork W2337574971 @default.
• W2116777199 hasRelatedWork W2981866216 @default.
• W2116777199 hasRelatedWork W3203771908 @default.
• W2116777199 hasRelatedWork W4285251055 @default.
• W2116777199 hasRelatedWork W4361800306 @default.
• W2116777199 hasRelatedWork W2156941679 @default.
• W2116777199 hasRelatedWork W4213406423 @default.
• W2116777199 hasVolume "15" @default.
• W2116777199 isParatext "false" @default.
• W2116777199 isRetracted "false" @default.

• next